Lumateperone for the Management of Schizophrenia and Neuropsychiatric Disorders

Course overview

Lumateperone is a second-generation antipsychotic approved for the treatment of schizophrenia and depressive episodes associated with bipolar I or II disorder, either as monotherapy or with lithium or valproate. It has a distinct mechanism of action, combining serotonin 5-HT2A receptor antagonism, dopamine D2 receptor modulation, and serotonin reuptake inhibition. This multimodal activity contributes to both antipsychotic and antidepressant effects. Compared to other atypical antipsychotics, lumateperone has a lower risk of metabolic side effects and extrapyramidal symptoms (EPS), making it a favorable option for patients with metabolic vulnerabilities. Unlike lurasidone, it does not require food for absorption, which may improve adherence.